ArticleTranslational andrology and urology2018

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial.

Isabel Heidegger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.